Screening of germline mutations in the CDK4, CDKN2C and TP53 genes in familial melanoma: A clinic-based population study

International Journal of Cancer

Volumn 78, Issue 1, 1998, Pages 13-15

  Platz, Anton ^a   Hansson, Johan ^a   Ringborg, Ulrik ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; DNA;

ARTICLE; CELL CYCLE; CONTROLLED STUDY; FAMILIAL CANCER; GENE MUTATION; GENETIC STABILITY; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; SWEDEN; TUMOR SUPPRESSOR GENE;

EID: 0031818039     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0215(19980925)78:1<13::aid-ijc3>3.0.co;2-%23     Document Type: Article

References (21)

1. DRACOPOLI, N.C., HARNETT, P., BALE, S.J., STANGER, B.Z., TUCKER, M.A., HOUSMAN, D.E. and KEFFORD, R.F., Loss of alleles from the distal short arm of chromosome 1 occurs late in melanoma tumor progression. Proc. nat. Acad. Sci. (Wash.), 86, 4614-4618 (1989).
2. FITZGERALD, M.G., HARKIN, P.D., SILVA-ARRIET, S., MCDONALD, D.J., LUCCHINA, L.C., UNSAL, H., O'NEILL, E., KOH, J., FINKELSTEIN, D.M., ISSLELBACHER, K.J., SOBER, A.J., and HABER, D.A., Prevalence of germ-line mutations in p16, p19ARF and CDK4 in familial melanoma: analysis of a clinic-based population. Proc. nat. Acad, Sci. (Wash.), 93, 8541-8545 (1996).
3. FLORES, J.F., POLLOCK, P.M., WALKER, G.J., GLENDENING, J.M., LINI A.H., PALMER, J.M., WALTERS. M.K., HAYWARD, N.K. and FOUNTAIN, J.W., Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds. Oncogene, 15, 2999-3005 (1997).
4. GREENE, M.H., CLARK, W.H., JR., TUCKER, M.A., KRAEMER, K.H., ELDER, D.E. and FRASER, M.C., High risk of malignant melanoma in melanomaprone families with dysplastic nevi. Ann. intern Med., 102, 458-465 (1985).
5. GRUIS, N.A. and 12 OTHERS, Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Amer. J. Pathol., 146, 1199-1206 (1995).
6. GUAN, K.L., JENKINS, C.W., LI, Y., NICHOLS, M.A., WU, X., O'KEEFE, C.L., MATERA, A.G. and XIONG, Y., Growth suppression by p18, a p16INK4/ MTS1 and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRB function. Genes Dev., 8, 2939-2945 (1994).
7. GULDBERG, P., KIRKIN, A.F., GRONBAEK, K., STRATEN, P.T., AHRENKIEL, V. and ZEUTHEN, J., Complete scanning of the CDK4 gene by denaturing gradient gel electrophoresis: a novel missense mutation but low overall frequency of mutations in sporadic metastatic malignant melanoma. Int. J. Cancer, 7, 780-783 (1997).
8. HUSSUSSIAN, C.J., STRUEWING, J.P., GOLDSTEIN, A.M., HIGGINS, P.A., ALLY, D.S., SHEAHAN, M.D., CLARK. W.H., JR., TUCKER, M.A. and DRACOPOLI, N.C., Germline p16 mutations in familial melanoma. Nature Genet., 8, 15-21 (1994).
9. KAMB, A. and 23 OTHERS, Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet., 8, 23-26 (1994).
10. NAITO, M., SATAKE, M., SAKAI, E., HIRANO, Y., TSUCHIDA, N., KANZAKI, H., ITO, Y. and MORI, T., Detection of p53 gene mutations in human ovarian and endometrial cancers by polymerase chain reaction-single strand conformation polymorphism analysis. Jap. J. Cancer Res., 83, 1030-1036 (1992).
11. OKAMOTO, A. and 13 OTHERS, Mutations in the P16INK4/MTS1 and P15INK4B/MTS2 and P18 genes in primary and metastatic lung cancer. Cancer Res., 55, 1448-1451 (1995).
12. PLATZ, A., HANSSON, J., MÅNSSON-BRAHME, E., LAGERLÖF, B., LINDER, S., LUNDQVIST, E., SEVIGNY, P., INGANÄS, M. and RINGBORG, U., Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with herditary cutaneous melanoma. J. nat. Cancer Inst., 89, 697-702 (1997).
13. 1 checkpoint control are frequently mutated in human melanoma metastases. Brit. J. Cancer, 74, 936-941 (1996).
14. SJÄLANDER, A., BIRGANDER, R., ATHLIN, L., STENLING, R., RUTEGÅRD, J., BECKMAN, L. and BECKMAN, G., p53 germ line haplotypes associated with increased risk for colorectal cancer. Carcinogenesis, 16, 1461-1464 (1995).
15. SJÄLANDER, A., BIRGANDER, R., HALLMANS, G., CAJANDEER, S., LENNER, P., ATHLIN, L., BECKMAN, G. and BECKMAN, L., p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis, 17, 1313-1316 (1996).
16. STONE, S., DAYANANTH, P., JIANG, P., WEAVER-FELDHAUS, J.M., TAVTIGIAN, S.V., CANNON-ALBRIGHT, L. and KAMB, A., Genomic structure, expression and mutational analysis of the p15 (MTS2) gene. Oncogene, 11, 987-991 (1995a).
17. STONE, S., JIANG, P., DAYANANTH, P., TAVTIGIAN, S.V., KATCHER, H., PARRY, D., PETERS, G. and KAMB, A., Complex structure and regulation of the p16 (MTS1) locus. Cancer Res., 55, 2988-2994 (1995b).
18. VARLEY, J.M., EVANS, D.G.R. and BIRCH, J.M., Li-Fraumeni syndrome - a molecular and clinical review. Brit. J. Cancer, 76, 1-14 (1997).
19. WALKER, G.J., HUSSUSSIAN, C.J., FLORES, J.F., GLENDENING, J.M,. HALUSKA, F.G., DRACOPOLI, N.C., HAYWARD, N.K. and FOUNTAIN, J.W., Mutations of the CDKN2/p16 INK4 gene in Australian melanoma kindred. Hum. mol. Genet., 4, 1845-1852 (1995).
20. ZARIWALA, M., LIU, E. and XIONG, Y., Mutational analysis of the p16 family cyclin-dependent kinase inhibitors p15 INK4b and p18INK4c in tumor-derived cell lines and primary tumors. Oncogene, 12, 451-455 (1996).
21. Zuo, L., WEGER, J., YANG, Q., GOLDSTEIN, A.M., TUCKER, M.A., WALKER, G.J., HAYWARD, N. and DRACOPOLI, N.C., Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nature Genet., 12, 97-99 (1996).